GET DAILY SIGNALSMaxCyte (MXCT) Stock Rises +43% in 30 Days on Q3 Momentum
Key Takeaways
- MaxCyte shares have climbed roughly 43% over the past 30 days, rising from about $1.18 to approximately $1.69.
- The move accelerated sharply on October 14 after the company reported preliminary third-quarter 2026 core revenue of about $8.1 million, up 26% year over year, and raised its full-year 2026 revenue guidance to approximately $34 million.
- Management attributed the third-quarter outperformance partly to accelerated instrument purchases from a large customer pulled forward from the fourth quarter, plus a $1.0 million Strategic Platform License (SPL) milestone.
- Sentiment has also been supported by a return to double-digit revenue growth and a deepening SPL pipeline, including the July 2026 multi-platform technology license agreement with Genentech, a member of the Roche Group.
- Over the trailing quarter, the stock has gained more than 60% from roughly $1.00 in late July, though the recent surge reflects meaningful day-to-day volatility.
- For deeper data on the company's outlook, explore MaxCyte's Price Targets, Earnings, and Forecast pages.
MaxCyte (MXCT) Company Overview and Market Position
MaxCyte, Inc. is a Rockville, Maryland-based cell-engineering company that provides enabling platform technologies for the discovery, development, and commercialization of next-generation cell therapies. Its core offering is the proprietary Flow Electroporation technology and the ExPERT platform, which allow biopharmaceutical and biotechnology customers to engineer a wide range of cell types and payloads. The company also offers gene-editing risk assessment services through its SeQure portfolio, including ONE-seq and GUIDE-seq, as well as newly launched CHANGE-seq-BE and ONE-seq-BE tools for evaluating off-target editing.
MaxCyte generates revenue through instrument sales and single-use processing assemblies, and increasingly through Strategic Platform License agreements under which partners pay annual fees, milestones, and royalties as programs advance toward and through commercialization. Because its platform supports many cell and gene therapy developers, investors follow MXCT as a broad, pick-and-shovel exposure to the cell therapy sector. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
MaxCyte (MXCT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, MXCT has risen from about $1.18 to approximately $1.69, a gain of roughly 43%. The advance was not linear: shares drifted lower through early October, reaching near $0.96 on October 13, before staging a decisive rally on October 14 that lifted the stock above $1.25 in a single session on sharply elevated volume.
The trailing quarter tells a similar but more pronounced story. From roughly $1.00 in late July, the stock has gained more than 60% to current levels. The broader trend reflects improving operating momentum rather than a single isolated event, though short-term moves have remained volatile given the company's relatively small float and lower trading liquidity.
What Drove MXCT Stock Price in the Last 30 Days
The primary catalyst was the October 14 announcement of preliminary third-quarter 2026 results and raised guidance. MaxCyte reported core business revenue of approximately $8.1 million, up 26% from the prior-year period, and SPL Program-related revenue of more than $1.0 million, including a $1.0 million milestone. The company raised its full-year 2026 revenue outlook to approximately $34 million, up from a prior range of $30 million to $32 million, with core business revenue expected near $28 million and SPL-related revenue near $6 million.
Investors responded by sending the stock up about 25% in a single session, with volume surging to more than 7.6 million shares versus a typical daily average well under one million. Management noted that the outperformance was driven in part by accelerated instrument purchasing from a large customer originally expected in the fourth quarter, along with a milestone from an SPL partner. Analysts have cautioned that a portion of the beat reflects the timing of a pulled-forward sale and that a share of the raised guidance includes one-time milestone revenue, making the durability of the growth a key focus. From what I see, this timing element deserves close attention in the coming quarters.
What Drove MXCT Stock Performance Over the Last Quarter
The quarterly advance reflects a broader narrative of a return to growth. After a challenging 2025, management entered 2026 targeting a second-half inflection, and the third-quarter update delivered evidence of double-digit revenue growth. Supporting sentiment, MaxCyte announced in July 2026 a multi-platform technology license agreement with Genentech to advance cell therapy development, expanding an enterprise partnership model that underscores the value of its SPL strategy.
Additional developments reinforced the theme, including the August 2026 launch of CHANGE-seq-BE and ONE-seq-BE for off-target assessment and the September appointment of a Chief Corporate Development Officer. Management has also emphasized that the company supports more late-stage clinical programs under its SPL partnerships than ever before, including two pivotal trials with potential for regulatory approval as early as next year. I’m watching this closely as the pipeline depth could provide further support.
MXCT Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor MaxCyte's third-quarter 2026 earnings call, scheduled for November 10, when full financial results including royalty revenue will be reported. Key areas of focus include the quality and sustainability of core revenue growth, whether the pulled-forward instrument purchases lead to a lighter fourth quarter, and any updates on SPL milestone and royalty activity. Progress on partner clinical programs—particularly the two pivotal trials management has highlighted—and any new Strategic Platform License agreements will be important demand signals. Macroeconomic conditions affecting biotech funding and sentiment toward the broader cell and gene therapy sector could also influence trading, especially given MXCT's comparatively small market capitalization and above-average volatility. One thing that stands out is how these factors could shape near-term volatility.
Exploring Systematic Trading Approaches
In my view, reviewing data-driven strategies can complement fundamental analysis for stocks like MXCT. Tickeron’s Trending AI Robots page offers a curated look at top-performing automated trading strategies. These bots cover different timeframes and risk profiles, providing a practical way to evaluate systematic ideas that align with individual objectives without replacing manual research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MXCT in +13.25% Uptrend, growing for three consecutive days on October 28, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MXCT advanced for three days, in 198 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on MXCT as a result. In 63 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for MXCT just turned positive on October 14, 2026. Looking at past instances where MXCT's MACD turned positive, the stock continued to rise in 34 of 47 cases over the following month. The odds of a continued upward trend are 72%.
MXCT moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MXCT crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MXCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
MXCT broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MXCT entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.112) is normal, around the industry mean (3.824). P/E Ratio (-5.029) is within average values for comparable stocks, (1.677). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (4.092) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. MXCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MXCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement